PTC Therapeutics, Inc. (PTCT:NSD) saw a reduction in its holdings by Pinnacle Associates Ltd., which sold 3,615 shares of the PTC stock during the fourth quarter of 2022, according to its most recent 13F filing with the Securities and Exchange Commission. The fund’s ownership in PTC Therapeutics, worth $6,936,000, represents a decrease of 2.0% at the end of the quarter.
Other institutional investors have bought and sold shares of the company, including MetLife Investment Management LLC, ProShare Advisors LLC, Diversified Trust Co, Altshuler Shaham Ltd, and Nisa Investment Advisors LLC.
PTC Stock Analysis:
It has been the subject of a number of analyst reports, with an average rating of “Hold” and an average price target of $49.55.
PTC stock performance shows a 1-year low of $25.01 and a 1-year high of $55.58, with a 50-day moving average price of $46.16 and a two-hundred day moving average price of $44.13.
Company Profile:
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.
PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
